pre-IPO PHARMA

COMPANY OVERVIEW

Chroma Medicine is a biotechnology company pioneering a new class of genomic medicines that harness epigenetics, nature's innate mechanism for gene regulation, to deliver precise, programmable single-dose therapeutics while preserving genomic integrity. The company was founded by the world's foremost experts in genomic research and is led by a veteran team of industry leaders and scientists with deep experience in genomic medicine, drug discovery, and development. For more information, please visit chromamedicine.com


LOCATION


THERAPEUTIC AREAS


WEBSITE

https://chromamedicine.com


CAREER WEBSITE

None


SOCIAL MEDIA


INVESTORS


PRESS RELEASES


Sep 27, 2023

Chroma Medicine Strengthens Leadership with the Appointment of Biotech Business Leader Michael A. Kelly to its Board of Directors


Sep 20, 2023

Chroma Medicine Presents Data Showing Specific and Durable HBV Silencing with Epigenetic Editors at the HBV International Meeting 2023


May 19, 2023

Chroma Medicine Announces Data Demonstrating the Benefits of Epigenetic Editing for Multiplex Gene Regulation at ASGCT 2023


May 18, 2023

Chroma Medicine Presents Data Demonstrating Near-Complete, Durable In Vivo Silencing with Targeted Epigenetic Editors at 2023 ASGCT Annual Meeting


May 2, 2023

Chroma Medicine to Present First Data Demonstrating Promise of Its Epigenetic Editing Platform at 26th ASGCT Annual Meeting


For More Press Releases


Google Analytics Alternative